UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1822, 2013

Angiotech Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

British Columbia

000-30334

98-0226269

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

~~1618~~355 ~~Station~~Burrard Street, Suite 1100, Vancouver, BC, Canada ~~V6A~~V6C ~~1B6~~2G8

(Address of principal executive offices)

(604) 221-7676

(Registrant’s Telephone Number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 21.0401. ~~Triggering~~Entry ~~Events~~Into ~~That~~Material ~~Accelerate~~Definitive ~~or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement~~Agreement.

OnStock ~~March 18,~~Purchase 2013, Angiotech Pharmaceuticals, Inc., a corporation organized under the laws of British Columbia (“Angiotech” or the “Company”), announced that, Deutsche Bank National Trust Company as trustee (the “Trustee”) under the Indenture (as defined below), issued a notice of redemption, filed herewith as Exhibit 99.1 and incorporated herein by this reference, to the record holder of the Company’s Senior Secured Floating Rate Notes due 2013 (the “Notes”, CUSIP Number 034918AH5) on behalf of Angiotech to redeem $16.0 million in aggregate principal amount of the Notes. The redemption price for the Notes is equal to 100% of principal amount of the Notes, together with any accrued and unpaid interest on the principal amount of the Notes to, but excluding, the redemption date, which is April 17, 2013. On the redemption date, the redemption price for the Notes will become due and payable. As of the date hereof, there are approximately $60.0 million in aggregate principal amount of Notes outstanding.Agreement

~~The~~On ~~Company~~March 22, ~~issued~~2013, ~~the~~Angiotech ~~Notes~~Pharmaceuticals, Inc., a corporation formed under ~~that~~the ~~certain~~laws ~~Indenture~~of ~~dated~~British asColumbia of(the ~~May 12~~“Company”), ~~2011~~Angiotech International AG, bya Swiss corporation (“AIAG”), and ~~among~~Angiotech ~~the~~Pharmaceuticals ~~Company~~(US), Inc., asa ~~issuer,~~Washington ~~certain~~corporation ~~subsidiaries~~(“AUS” ofand, collectively with the Company asand ~~guarantors~~AIAG, ~~referred~~the to“Sellers”) ~~therein~~entered ~~and~~into ~~the~~a ~~Trustee,~~Stock asPurchase ~~supplemented~~Agreement bydated ~~that~~March 22, ~~certain~~2013 ~~Supplemental~~(the ~~Indenture,~~“SPA”) ~~dated~~with asArgon ofMedical ~~August~~Devices Holdings, 13Inc., ~~2012,~~a ~~among~~Delaware ~~the~~corporation ~~Company~~(“Argon Holdco”), ~~the~~Argon ~~guarantors~~Medical ~~referred~~Devices, Inc., toa ~~therein~~Delaware corporation (“Argon”), and ~~the~~Argon ~~Trustee~~Medical ~~(the~~Devices ~~indenture~~Netherlands B.V., asa ~~supplemented,~~private ~~referred~~company towith aslimited liability incorporated under the laws of the Netherlands (“~~Indenture~~Argon Netherlands”). ~~The~~and, ~~redemption~~collectively ~~will~~with beArgon, ~~made~~“Buyers”). AIAG ~~pursuant~~and toAUS ~~the~~are ~~terms~~subsidiaries of the ~~Indenture~~Company.

~~Item~~Pursuant 8to the terms of the SPA, the Sellers agreed to sell to Buyers substantially all corporate entities, manufacturing, commercial and administrative operations relating to the Company’s Interventional Products business for $362.015 million in cash, subject to a post-closing working capital adjustment. ~~Other~~The ~~Events~~Sellers will receive $347.5 million upon the close of the transaction, and $15 million shall be retained in escrow for a period of 12 months to secure indemnification obligations of the Sellers.

OnThe ~~March 18~~completion of the transactions described in the SPA (the “Transaction”) is subject to various conditions, ~~2013~~including, ~~Angiotech~~among ~~issued~~others, athe ~~press~~termination ~~release~~or ~~announcing~~expiration of applicable waiting periods under the ~~partial~~Hart-Scott-Rodino ~~redemption~~Antitrust Improvements Act of 1976, as amended. The completion of the ~~Notes~~Transaction is also subject to approval of the Company’s shareholders. AShareholders ~~copy~~representing approximately 70% of ~~Angiotech~~the Company’s ~~press~~outstanding ~~release~~shares ishave ~~furnished~~signed asvoting ~~Exhibit 99~~agreements in connection with the Transaction, agreeing to vote their shares in favor of the Transaction.2 Subject to ~~this~~the ~~Current~~satisfaction ~~Report~~or onwaiver ~~Form~~of conditions in the SPA, the Company expects the transaction to close by the end of April ~~8-K~~2013.

Item 98.01. ~~Financial~~Other ~~Statements and Exhibits~~Events.

~~(d)~~On March ~~Exhibits~~25, 2013, the Company issued a press release to announce the Transaction. The ~~following~~press ~~exhibits~~release ~~are~~is ~~filed~~attached ~~herewith:~~hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

Exhibit		Description
99.1		Notice of Optional Partial Redemption dated March 18, 2013.
99.2		Press Release, dated March 18, 2013.

Item 9.01. Financial Statements and Exhibits.

2(d) Exhibits. The following exhibits are filed herewith:

SIGNATURE

Exhibit		Description

99.1		Press Release, dated March 25, 2013.

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2

	ANGIOTECH PHARMACEUTICALS, INC.
	(Registrant)
Date: March 19, 2013	By:	/s/ K. Thomas Bailey
		K. Thomas Bailey
		Chief Executive Officer

SIGNATURE

3Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX

	ANGIOTECH PHARMACEUTICALS, INC.
	(Registrant)


Date: March 26, 2013	By:	/s/ K. Thomas Bailey
		K. Thomas Bailey
		Chief Executive Officer

Exhibit		Description
99.1		Notice of Optional Partial Redemption dated March 18, 2013.
99.2		Press Release, dated March 18, 2013.

4EXHIBIT INDEX

Exhibit		Description

99.1		Press Release, dated March 25, 2013.

Filing Compare · ANGIOTECH PHARMACEUTICALS INC